Modulo

-22%

est. 2Y upside i

HealthcareSeries A

Modulo is a Biotech company working to reprogram the brain’s immune system to cure neurodegenerative disorders.

Rank

#2809

Sector

Biotechnology

Est. Liquidity

~3Y

Data Quality

Data: Low

Equity in Modulo Bio carries very high risk given its early stage, no revenue, and dominant competition.

Last updated: July 19, 2026

Bull (10%)+233%

Positive clinical data leads to acquisition at $80M, 4x current valuation, but 20% dilution lowers net upside to 233%.

Base (50%)-10%

Steady progress, no major catalyst; valuation flat at $20M with 20% dilution reduces per-share value by ~10%.

Bear (40%)-100%

Clinical failure or significant setback; valuation collapses to $0, common equity worthless.

Est. time to liquidity~3.0 years

Preference Stack Risk

severe

Funding Intensity

69%

Total funding of $13.8M represents 69% of current assumed $20M valuation; in any exit below $13.8M, common equity gets nothing.

Dilution Risk

high

Expected to raise additional capital within 2 years, potentially diluting existing holders by 20% or more.

Secondary Liquidity

none

No secondary market exists for this early-stage private company.

Other — 1 role

Careers · Please reach out and let us know more about you and what you’re looking for.

Last updated: February 22, 2026

Questions to Ask at the Interview

Strategic questions based on Modulo's data — designed to show you've done your homework.

1
“How does your platform compare to incumbents like Biogen's approaches?”
2
“What milestones are you targeting in the next 2 years to increase valuation?”
3
“Given the high burn rate, how will you manage equity dilution for early employees?”

Our model estimates -22% upside. What do you think?

Anonymous. Do not share material non-public information.

Comments are reviewed before they appear publicly.

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.